



PATENT  
Docket No. 205032001200

#8/D  
B.H.  
2-28-03

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 3, 2003.

*Judy Bridgewater*  
Judy Bridgewater

TECH CENTER 1600/2900

FEB 12 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ta-Shuong YEH, *et al.*

Serial No.: 09/847,017

Filing Date: May 1, 2001

For: A PROCESS FOR THE PREPARATION  
OF DIRECT TABLETTING  
FORMULATION AND AIDS

Examiner: Todd Ware

Group Art Unit: 1615

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is supplemental to an amendment filed on January 2, 2003 in response to an Office action herein mailed October 1, 2002. This supplemental amendment includes the amendments and remarks set forth in the amendment filed January 2, 2003 and also includes an additional new claim and new remarks, and therefore, may be considered in lieu of the amendment filed January 2, 2003. The Office action set a time for response to expire on January 1, 2003. As February 1, 2003 fell on a Saturday, this submission is timely filed on Monday February 3, 2003 with a petition for a one-month extension of time and the required fee. Claims 1-33 were rejected in the Office action. Careful consideration has been given to the grounds for rejection and the following amendments and remarks are offered in response. Reconsideration is

02/10/2003 HDAWTE1 00000057 09847017

02 FC:2202 9.00 CH

sd-130355

respectfully requested. Enclosed is an exhibit entitled "Marked Version of Amendments to the Claims" (Exhibit A). A copy of an article entitled "Current issues and trouble shooting fluid bed granulation," reprinted from *Pharmaceutical Technology* May 1998 from the http address [www.niroinc.com/html/pharma/phpdfs/micropoint2.pdf](http://www.niroinc.com/html/pharma/phpdfs/micropoint2.pdf) was included as Exhibit B in the amendment filed January 2, 2003.